We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Dysregulation of Retinoic Acid Signaling in Stem Cells Spurs Tumor Growth

By LabMedica International staff writers
Posted on 05 Nov 2018
A team of cancer researchers identified the retinoic acid molecular signaling pathway as being a factor that helps to prevent the development of colorectal cancer.

Investigators at the Christiana Care Health System (Wilmington, DE, USA) were studying the factors controlling the differentiation of colon cancer stem cells (SCs) into undifferentiated tumor cells or, in some cases, into differentiated (non-cancerous) colon cells. More...
Since tumor development is driven by stem cell overpopulation, and in light of earlier findings that the enzyme aldehyde dehydrogenase (ALDH) was both a marker for SCs in many tissues and a key enzyme in retinoid acid (RA) signaling, the investigators examined RA signaling in normal and malignant colonic SCs.

The investigators analyzed normal and malignant colonic tissues and colorectal cancer (CRC) cell lines to see if retinoid receptors (RXR & RAR) were exclusively expressed in ALDH+ SCs, and if RA signaling changed during CRC development. Specifically, they determined whether RA signaling regulated cancer SC proliferation, differentiation, sphere formation, and population size.

Results published in the October 5, 2018, online edition of the journal Oncotarget revealed that RXR & RAR were expressed in ALDH+ colonic SCs, but not in normal cells. Western blotting/immunostaining of CRCs revealed that RA signaling components became overexpressed in parallel with ALDH overexpression, which coincided with the known overpopulation of ALDH+ SCs that occurs during, and drives, CRC development.

Treatment of SCs with all-trans retinoic acid (ATRA) was found to decrease proliferation, sphere formation, and ALDH+ SC population size and to induce differentiation. Thus, dysregulation of RA signaling in colonic SCs likely contributed to overpopulation of ALDH+ SCs and CRC growth.

“Our findings point to a number of possibilities for developing more effective stem cell targeting therapies for advanced colorectal cancer,” said senior author Dr. Bruce Boman, a senior research scientist at the Christiana Care Health System. “Our thinking has shifted to the insight that cancers originate in tissue stem cells through dysregulation or malfunction of the self-renewal process, and that cancer stem cells drive tumor growth. It follows that the optimal way to treat cancer (especially advanced cancer) is to eliminate cancer stem cells. We discovered that the retinoic acid or RA signaling pathway acts to induce differentiation of colon cancer stem cells and reduce cancer stem cell overpopulation, which puts the brakes on the primary mechanism that drives colon cancer development.”

Related Links:
Christiana Care Health System


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.